Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Jyoti Mayadev; Dmitriy Zamarin; Wei Deng; Heather Lankes; Roisin O'Cearbhaill; Carol A Aghajanian; Russell Schilder

doi:10.1136/ijgc-2019-001012

Citation Tools

This article has corrections. Please see:

Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer - July 01, 2020
Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer - August 01, 2020

other Versions

You are currently viewing an earlier version of this article (September 22, 2020).
View the most recent version of this article

Clinical trial

Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Mayadev J, Zamarin D, Deng W, et al

Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

International Journal of Gynecologic Cancer Published Online First: 22 December 2019. doi: 10.1136/ijgc-2019-001012

Log in using your username and password

Main menu

Log in using your username and password

You are here

This article has corrections. Please see:

other Versions

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password